Pharsight

Drugs that contain Dexamethasone

1. Dextenza patents expiration

DEXTENZA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9254267 OCULAR THERAPEUTIX Composite hydrogel drug delivery systems
Sep, 2024

(3 months from now)

US8563027 OCULAR THERAPEUTIX Drug delivery through hydrogel plugs
Feb, 2030

(5 years from now)

US8409606 OCULAR THERAPEUTIX Drug delivery through hydrogel plugs
May, 2030

(5 years from now)

US11458041 OCULAR THERAPEUTIX Punctal plug and bioadhesives
Nov, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-876) Oct 07, 2024
New Indication(I-800) Jun 20, 2022
New Product(NP) Nov 30, 2021

Market Authorisation Date: 30 November, 2018

Treatment: Dextenza is approved for the treatment of ocular pain following ophthalmic surgery; Treatment of ocular inflammation and pain following ophthalmic surgery

Dosage: INSERT;OPHTHALMIC

More Information on Dosage

DEXTENZA family patents

Family Patents

2. Dexycu Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7560120 EYEPOINT PHARMS Vehicles for delivery of biologically active substances
Sep, 2022

(1 year, 8 months ago)

US6960346 EYEPOINT PHARMS Vehicles for delivery of biologically active substances
Jul, 2023

(10 months ago)

US10799642 EYEPOINT PHARMS Dose guides for injection syringe
May, 2032

(7 years from now)

US10159683 EYEPOINT PHARMS Use of sustained release dexamethasone in post-cataract surgery inflammation
May, 2034

(9 years from now)

US10028965 EYEPOINT PHARMS Use of sustained release dexamethasone in post-cataract surgery inflammation
May, 2034

(9 years from now)

US10022502 EYEPOINT PHARMS Dose guides for injection syringe
Jun, 2034

(10 years from now)

US11097061 EYEPOINT PHARMS Systems, kits and methods for loading and delivering a small volume dose from a syringe
Jun, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Feb 09, 2021

Market Authorisation Date: 09 February, 2018

Treatment: Treatment of postoperative inflammation; A method of loading medication into a syringe and delivering the medication to a treatment site

Dosage: SUSPENSION;INTRAOCULAR

More Information on Dosage

DEXYCU KIT family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Hemady patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11304961 DEXCEL Compositions comprising dexamethasone
Dec, 2037

(13 years from now)

US10537585 DEXCEL Compositions comprising dexamethasone
Dec, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-271) Oct 03, 2026

Market Authorisation Date: 03 October, 2019

Treatment: A method of treating adults with multiple myeloma using dexamethasone in combination with an anti-myeloma product

Dosage: TABLET;ORAL

More Information on Dosage

HEMADY family patents

Family Patents

4. Ozurdex patents expiration

OZURDEX's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6726918 ABBVIE Methods for treating inflammation-mediated conditions of the eye
Oct, 2020

(3 years ago)

US8043628 ABBVIE Methods for reducing edema
Oct, 2020

(3 years ago)

US9012437 ABBVIE Implants and methods for treating inflammation-mediated conditions of the eye
Oct, 2020

(3 years ago)

US7033605 ABBVIE Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
Oct, 2020

(3 years ago)

US8088407 ABBVIE Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
Oct, 2020

(3 years ago)

US9775849 ABBVIE Implants and methods for treating inflammation-mediated conditions of the eye
Oct, 2020

(3 years ago)

US8063031 ABBVIE Implants and methods for treating inflammation-mediated conditions of the eye
Oct, 2020

(3 years ago)

US9592242 ABBVIE Methods for treating edema in the eye and intraocular implants for use therefor
Oct, 2020

(3 years ago)

US9283178 ABBVIE Methods for treating edema in the eye and intraocular implants for use therefor
Oct, 2020

(3 years ago)

US7767223 ABBVIE Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use
Nov, 2021

(2 years ago)

US9192511 ABBVIE Ocular implant made by a double extrusion process
Jan, 2023

(1 year, 4 months ago)

US10702539 ABBVIE Ocular implant made by a double extrusion process
Jan, 2023

(1 year, 4 months ago)

US10076526 ABBVIE Ocular implant made by a double extrusion process
Jan, 2023

(1 year, 4 months ago)

US8506987 ABBVIE Ocular implant made by a double extrusion process
Jan, 2023

(1 year, 4 months ago)

US8034370 ABBVIE Ocular implant made by a double extrusion process
Jan, 2023

(1 year, 4 months ago)

US8034366 ABBVIE Ocular implant made by a double extrusion process
Jan, 2023

(1 year, 4 months ago)

US6899717 ABBVIE Methods and apparatus for delivery of ocular implants
Nov, 2023

(6 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Jun 17, 2012
New Indication(I-686) Jun 29, 2017
Orphan Drug Exclusivity(ODE) Sep 24, 2017

Market Authorisation Date: 17 June, 2009

Treatment: Treatment of uveitis; Treatment of macular edema; Intravitreal treatment of diabetic macular edema; Treatment of non-infectious uveitis affecting the posterior segment of the eye; Delivering an ocular...

Dosage: IMPLANT;INTRAVITREAL

More Information on Dosage

OZURDEX family patents

Family Patents